Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19643877 | 0.85 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL20985774 | 0.82 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL19643895 | 0.81 | ROCK2 (0.83) | ROCK2 | |
| SCHEMBL19643781 | 0.81 | ROCK2 (0.67) | ROCK2 | |
| SCHEMBL19643894 | 0.79 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL17913016 | 0.77 | PKM (0.66) | ROCK2ROCK1 | |
| SCHEMBL19643172 | 0.77 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL19643226 | 0.74 | ROCK2 (0.59) | ROCK2 | |
| SCHEMBL19643644 | 0.74 | ROCK2 (0.60) | ROCK2ROCK1 | |
| SCHEMBL19643883 | 0.73 | ROCK2 (0.61) | ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464262-B1 | TRIAZOLONES AND TETRAZOLONES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-02-26 | — | — | EP | claimed |
| US-10562887-B2 | Triazolones and tetrazolones as inhibitors of ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-02-18 | — | — | US | claimed |
| CN-109153663-B | Triazolones and tetrazolones as ROCK inhibitors | 百时美施贵宝公司 | 2021-08-13 | — | — | CN | disclosed |
| EP-3464262-B1 | TRIAZOLONES AND TETRAZOLONES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-02-26 | — | — | EP | disclosed |
| EP-3464262-B1 | TRIAZOLONES AND TETRAZOLONES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-02-26 | — | — | EP | disclosed |
| US-10562887-B2 | Triazolones and tetrazolones as inhibitors of ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-02-18 | — | — | US | disclosed |
| US-10562887-B2 | Triazolones and tetrazolones as inhibitors of ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190152956-A1 | TRIAZOLONES AND TETRAZOLONES AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-05-23 | — | — | US | disclosed |
| US-20190152956-A1 | TRIAZOLONES AND TETRAZOLONES AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-05-23 | — | — | US | disclosed |
| EP-3464262-A1 | TRIAZOLONES AND TETRAZOLONES AS INHIBITORS OF ROCK | Bristol-Myers Squibb Company (US) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017205709-A1 | TRIAZOLONES AND TETRAZOLONES AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017205709-A1 | TRIAZOLONES AND TETRAZOLONES AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152956-A1 | TRIAZOLONES AND TETRAZOLONES AS INHIBITORS OF ROCK | MYLK, ROCK1, MYLK2 | ROCK2 5/4885ROCK1 2/4885 |
| US-10562887-B2 | Triazolones and tetrazolones as inhibitors of ROCK | MYLK, ROCK1, MYLK2 | ROCK2 5/4885ROCK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.